Ole Jannik Bjerrum

Ole Jannik Bjerrum

Professor, emeritus


  1. Published

    A Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory Science: Workshop Proceedings and Commentary

    Borup, G., Bach, K. F., Schmiegelow, M., Kildemoes, H. W., Bjerrum, Ole Jannik & Westergaard, N., May 2016, In: Therapeutic Innovation & Regulatory Science. 50, 3, p. 304-311 8 p.

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Published

    A novel inhibitor of advanced glycation end- product formation inhibits mesenteric vascular hypertrophy in experimental diabetes

    Bjerrum, Ole Jannik, 1999, In: Diabetologica. 42, p. 472-479 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    A simple method for the preparation and purification of C1 complement cleaved beta 2-microglobulin from human serum.

    Nissen, Mogens Holst, Johansen, B. & Bjerrum, Ole Jannik, 1997, In: Journal of Immunological Methods. 205, 1, p. 29-33 4 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    An analysis of the fixed-dose combinations authorized by the European Union, 2009-14: A Focus on benefit-risk and clinial development condition

    Sawicki-Wrzask, D., Thomsen, M. & Bjerrum, Ole Jannik, 2015, In: Therapeutic Innovation & Regulatory Science. 49, 4, p. 553-559 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA's and FDA's Views on Initial Dual-Therapy

    Bjerrum, Ole Jannik, Eichendorff, S. & Alkis, N. B., Mar 2020, In: Therapeutic Innovation & Regulatory Science. 54, 2, p. 297-302 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy

    Bjerrum, Ole Jannik, Eichendorff, S. & Alkis, N. B., 2019, In: Therapeutic Innovation & Regulatory Science. 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Body of evidence and approaches applied in the clinical development programme of fixed-dose combinations in the European Union from 2010 to 2016

    Nøhr-Nielsen, A., De Bruin, M. L., Thomsen, M., Pipper, C. B., Lange, Theis, Bjerrum, Ole Jannik & Lund, Trine Meldgaard, 2019, In: British Journal of Clinical Pharmacology. 85, 8, p. 1829-1840 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Centrally mediated anti-noceptive action of GABAA receptor agonists in the spared nerve injury model of neuropathic pain

    Bjerrum, Ole Jannik, 2005, In: European Journal of Pharmaceutical Sciences. 516, p. 131-138 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Co-administered gabapentin and venlafaxine in nerve injured rats: effect on mechanical hypersensitivity, motor function and pharmacokinetics

    Folkesson, A. J. M., Honoré, P. G. H. & Bjerrum, Ole Jannik, 2009, In: Scandinavian Journal of Pain. 1, 2, p. 91-97

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen) and phenobarbital in human volunteers

    Lappin, G., Shishikura, Y., Jochemsen, R., Weaver, R. J., Gesson, C., Houston, J. B., Oosterhuis, B., Bjerrum, Ole Jannik, Grynkiewicz, G., Alder, J., Rowland, M. & Garner, C., 20 Apr 2011, In: European Journal of Pharmaceutical Sciences. 43, 3, p. 141-150 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 Next

ID: 1302721